ScholarIQanswers from OpenAlex
Bayer (United States)
InstitutionResearch output, impact & collaborations
Bayer (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Bayer (United States)?
ScholarIQrecord summary
Bayer (United States) is a research organisation in Whippany, US. OpenAlex records 8,509 works and 1,095,589 citations for it. 2,638 researchers list it as their most recent affiliation.
How many works does Bayer (United States) have?
ScholarIQindexed works
Bayer (United States) has 8,509 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bayer (United States) have?
ScholarIQcitation count
Bayer (United States) has 1,095,589 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Bayer (United States)?
ScholarIQresearcher count
Bayer (United States) has 2,638 researchers in the ScholarIQ index.
What is the average h-index at Bayer (United States)?
ScholarIQavg h-index
Bayer (United States) has an average h-index of 27.3 in OpenAlex.
What is the ROR of Bayer (United States)?
ScholarIQror
The ROR for Bayer (United States) is on the source record.
What is the OpenAlex record for Bayer (United States)?
ScholarIQopenalex
The OpenAlex for Bayer (United States) is on the source record.
Who are the most-cited researchers behind Bayer (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Bayer (United States)?
ScholarIQmost cited works
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
Nathan R. Hill, Samuel Fatoba, Jason Oke, Jennifer Hirst, Christopher A. O’Callaghan, Daniel Lasserson, Richard Hobbs
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph, Gerasimos Filippatos
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, Stefan D. Anker, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Martin Gebel, Luís M. Ruilope, George L. Bakris, FIDELIO-DKD and FIGARO-DKD investigators
Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics
Timothy P. Padera, Ananth Kadambi, Emmanuelle di Tomaso, Carla Mouta Carreira, Edward B. Brown, Yves Boucher, Noah C. Choi, Douglas J. Mathisen, John Wain, Eugene J. Mark, Lance L. Munn, Rakesh K. Jain
Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?
Hans‐Georg Eichler, Sheldon X. Kong, William C. Gerth, Panagiotis Mavros, Bengt Jönsson
How much of the research on Bayer (United States) is open access?
ScholarIQopen access share
92%OPEN ACCESS